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Abstract 
Cathepsins are an important category of enzymes that have attracted great attention for the 
delivery of drugs to improve the therapeutic outcome of a broad range of nanoscale drug delivery 
systems. These proteases can be utilized for instance through actuation of polymer-drug 
conjugates (e.g., triggering the drug release) to bypass limitations of many drug candidates. A 
substantial amount of work has been witnessed in the design and the evaluation of Cathepsin-
sensitive drug delivery systems, especially based on the tetra-peptide sequence (Gly-Phe-Leu-
Gly, GFLG) which has been extensively used as a spacer that can be cleaved in the presence of 
Cathepsin B. This Review Article will give an in-depth overview of the design and the biological 
evaluation of Cathepsin-sensitive drug delivery systems and their application in different 
pathologies including cancer before discussing Cathepsin B-cleavable prodrugs under clinical 
trials. 
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1. Introduction 
 
Cathepsins are widely known proteolytic enzymes whose main function is to degrade proteins or 
peptides [1]. Nevertheless, this perception has changed over the past many years as they are 
being considered as important signaling molecules playing different crucial roles [2, 3]. There 
are dozens of Cathepsins which are classified according to their structure, catalytic mechanism 
and substrate. Based on the human genome draft sequence, the main Cathepsin categories are 
serine (Cathepsin A and G), aspartic (Cathepsin D and E) and lysosomal cysteine proteases 
(Cathepsin B,C,F,H,K,L1,L2/V,O,S,W,X/Z) [4, 5]. They have multiple functions, as one finds 
digestive proteases (present in saliva, stomach and intestines) for food processing inside the 
gastrointestinal tract (GIT), lysosomal proteases for intracellular housekeeping or caspases for 
transduction of one-way signal in apoptosis [6-8]. Interestingly, lysosomal Cathepsins (i.e., 
intracellular enzymes) have been widely involved in drug targeting as they require a slightly 
acidic environment to exhibit optimal enzymatic activity [9-11]. Given the features of disease-
associated proteolysis (i.e., cleavage of amide bond), different types of prodrugs, nanocarriers, 
biomaterials or probes, have been designed and synthesized to exert their activity in 
endosomal/lysosomal compartments [12-14]. For instance, Cathepsins can induce the release of 
active ingredients from nanocarriers, chemically or physically, leading to enhanced therapeutic 
activity or in situ imaging sensitivity [15]. Kopecek, Duncan and others have shown the 
importance of protease-cleavable linkers, especially those sensitive to Cathepsin B, in polymer-
based, nanoscale drug delivery constructs for enhancing the in vivo delivery of drugs to tumor 
tissues [16-18]. 
Cysteine cathepsins and their substrate interaction have been well-identified on the basis 
of papain (Carica papaya) used as a model of lysosomal proteases, as first introduced by 
Schechter and Berger [19]. In this model, the substrate residues (P) as well as the subsites (S) 
were given nomenclature based on their position bonded to the protease surface. Later, this 
model was revisited by Turk et al. [20]who showed that the subsites were positioned on the left-
hand side (i.e., S2’, S1 and S3) along with right-hand side of the active site (i.e., S1’ and S2), and 
further composed of two L-domain loops consisting of Gln-19–Cys-25 as well as Arg-59–Tyr-67 
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residues and two R-domain loops consisting of Leu-134–His-159 as well as Asn-175–Ser-205 
residues (Figure 1) [5]. 
 
Figure 1.Schematic representation of the revised papain model showing different subsites based 
on substrate-mimicking inhibitors bonded to the active-site cleft. Reproduced with permission 
from Ref. [5]. 
Among the different pathologies, Cathepsins have been largely employed as leverage to treat 
cancer from various Cathepsin-sensitive drug delivery systems because of its overexpression at 
the tumor sites. For instance, cysteine proteases have increased activity as well as aberrant 
localization within the tumour microenvironment, which contributes to cancer progression, 
proliferation and metastasis [21]. Such findings led to the development of the glycyl-
penylalanyl-leucyl-glycine (GFLG) sequence that is hydrolyzed by Cathepsin B. In this area, 
poly(N-(2-hydroxypropyl)methacrylamide-doxorubicin (PHPMA-Dox, also called PK1) were 
the first clinically investigated conjugates for anticancer therapy that comprised Cathepsin-
sensitive degradable GFLG sequences [22]. Since PK1, several PHPMA-drug conjugates have 
entered clinical trials [23, 24], which confirmed the great potential of these systems. Some of the 
structures of the different drug delivery conjugates are gathered in Figure 2 along with their 
cathepsin cleavable sites for better understanding [25-27]. 
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Figure 2. Structure of different cathepsin-sensitive drug-linker bioconjugates along with their 
indicated cleavable sites. 
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Whereas several reviews have already been published on targeted polymer-based drug delivery 
systems [28-31], cysteine Cathepsins as imaging probes [32-35], ageing and neurodegeneration 
[36], disease management [37] and other protease functions [38, 39], the dynamic involvement 
of Cathepsins in targeted drug delivery systems including their role in various diseased states and 
their clinical prospects have never been covered in a single Review Article. 
 
2. Cathepsin-sensitive drug delivery systems 
2.1 Anticancer drug delivery systems 
In the past few decades, anticancer drug delivery has attracted extensive interest from both 
academia and industry. A considerable effort is being spent on the design of nanoscale systems 
having suitable properties for drug delivery purposes such as stealthiness, non-immunogenicity, 
biocompatibility as well as biodegradability. The fate of stealth nanoscale systems is governed, 
at least in part, by the enhanced permeability and retention (EPR) effect (also called passive 
targeting). It allows for their preferential accumulation at the tumor site because of leaky 
vasculatures and lack of lymphatic drainage [40, 41]. Interestingly, a variety of different 
Cathepsins have been reported to be overexpressed in many types of cancers; mostly found in 
cancer cells but also in cancer-associated leukocytes, fibroblasts, osteoclasts, myoepithelial cells 
as well as endothelial cells [42]. The list of cancer overexpressing Cathepsins is given below 
(Table 1). Hence, the intimate relationships between Cathepsins and cancer stimulated the 
conception of (macro)molecules sensitive to the presence of Cathepsins for enhanced therapeutic 
effect. 
 
 
 
 
 
 
 
 
7 
 
Table 1. List of Cathepsin Overexpressing Cancer Types. 
Family Cathepsin Location Tumour site Reference 
Cysteine 
Proteases 
General 
Intracellular, 
lysosomes 
Most [42-44] 
Cathepsin K Extracellular Breast, bone [45-49] 
Cathepsin B 
Extracellular and 
pericellular 
under 
pathological 
conditions 
Breast, cervix, 
colon, colorectal, 
gastric, head and 
neck, liver, lung, 
melanoma, 
ovarian, 
pancreatic, 
prostate, thyroid 
[50-61] 
 
Cathepsin L  Breast, colorectal [62-65] 
Aspartic 
Proteases Cathepsin E 
Endosomal 
structures, ER, 
Golgi bodies 
Cervical, gastric, 
lung, pancreas 
adenocarcinomas 
[61, 66-70] 
Cathepsin D Lysosomes 
Breast, 
colorectal, 
ovarian 
[71-77] 
 
In the following, we have covered Cathepsin-sensitive drug delivery systems for anticancer 
therapy, by distinguishing five different types of systems: (i) polymeric; (ii) inorganic; (iii) 
dendritic/comb-like; (iv) lipidic and (v) protein-based/peptidic.  
 
2.1.1 Polymeric systems 
Different types of polymeric systems have been utilized to develop drug-polymer conjugates for 
anticancer drug delivery [28, 78-85]. Given Cathepsin B is a lysosomal cysteine protease 
overexpressed in the microenvironment of advanced tumors [86], this feature has been widely 
exploited in cancer therapy using polymer-based drug delivery systems bearing the Cathepsin B-
sensitive GFLG sequence [87]. This area was pioneered by Kopeck who developed PHPMA-
based drug conjugates containing GFLG sequences on the polymer backbone as well as on the 
side-chains,giving enhanced therapeutic efficacy while still maintaining their biocompatibility. 
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This system was further extended to a two-drug combination approach using gemcitabine (Gem, 
unstable in vivo) and paclitaxel (Ptx, poorly water soluble) linked to either diblock, tetrablock or 
hexablock PHPMA copolymers obtained by a combining RAFT polymerization and “click” 
chemistry (Figure 3). The diblock copolymer (Mn~100 kDa) was found to be the most efficient 
one in vivo on A2780 human ovarian carcinoma xenografts in nude mice. It indeed showed a 
more pronounced synergistic antitumor effect compared to other structures, thus overcoming the 
limitations of the free drug. 
 
Figure 3. Illustration of GFLG-containing PHPMA prodrugs. Adapted with permission from ref. 
[87]. 
 
The strongest synergistic interactions in acute myeloid leukemia (AML) was also observed as 
assessed in HL-60 human AML cells when cytarabine and GDC-0980 were linked to similar 
GFLG-bearing PHPMA copolymers, conversely to daunorubicin or JS-K [88]. Similarly, another 
study reported on the combination of GDC-0980 (P13K/mTOR inhibitor) and docetaxel against 
prostate cancer and showed promising results (Figure 4) [89]. Several other combinations 
directed against cancer have also been explored from PHPMA copolymer bearing GFLG 
sequences [90-94]. 
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Figure4. GFLG-containing PHPMA prodrugs for combination therapy (GDC-0980 and 
docetaxel) for prostate cancer exhibiting effective anti-Cancer Stem Cell (CSC) effect and in 
vitro increased anti-bulk tumor effect. Adapted with permission from Ref. [89]. 
 
In a more mechanistic study, two PHPMA-based multiblock S-CMP (small copolymer block 
size) and L-CMP (long copolymer block size) have been synthesized [95]. Both the copolymer 
blocks and the peptide linkers were tagged with 
125
I and 
177
Lu, respectively (Figure 5). S-CMP 
showed increased cleavage rates by Cathepsin S compared to L-CMP resulting from the lower 
steric hindrance as assessed by in vitro studies. The cleavage and clearance of the different 
blocks were both greater inside the tumor and the liver, as observed from radioisotopic ratios. 
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Figure5. Chemical structure of PHPMA-based, dual-labeled small copolymer block size (S-
CMP) and long copolymer block size (L-CMP) showing cleavage sites for CathepsinS [95]. 
 
Dox has been conjugated to different polymeric architectures via Cathepsin-sensitive linkers. For 
instance, Dox was linked to an octa-guanidine-based peptide sequence (Phe-Lys) via 4-
aminobenzyloxy carbonyl (PABC) as a self-immolative linker, resulting in a G8-PP1-FK-PABC-
Doxprodrug. It was able to be cleaved by lysosomal Cathepsin B and inducing selective toxicity 
against HeLa cells without affecting healthy cells [96].On the contrary, small-molecule 
(MW<500 g.mol
-1
) self-assemblies have also been utilized to develop a generic cross-linked 
micellar drug delivery system based on gemcitabine (Gem) prodrugs (Figure 6a). This system 
proved to be advantageous as compared to well-known polymeric micellar systems in terms of 
composition, colloidal stability, drug payload (~58 wt.%), biosafety, as well as ease of synthesis, 
functionalization and in vitro/in vivo anticancer activity [97-99]. Infact, nearly 60% of the drug 
was released from the micelles by Cathepsin B in phosphate buffer saline (PBS) at pH 5.5 for 
240 h conversely to <7% without Cathepsin B because of the amide bond in between the drug 
and the promoiety (Figure 6b) [100]. 
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Figure6. Chemical structure of the gemcitabine prodrug (a) and in vitro drug release profile from 
the gemcitabine prodrug micellar system (b). Adapted with permission from Ref. [100]. 
 
Another report focused on the construction of PEGylated, enzyme-sensitive,macrocyclic 
pillar[5]arene amphiphiles which self-assembled in water into micelles with high Dox loading 
capacity [101]. The micelles had enzyme-cleavable amide bonds that were cleaved by L-
asparaginase (L-ASP) used here as a mimic of intracellular Cathepsin B because it can catalyze 
the hydrolysis of asparagine to aspartic acid (Figure 7). The Dox-loaded micelles led to 
significant cytotoxicity on MCF-7 and multidrug-resistant MCF-7/ADR cells, comparatively to 
drug-free micelles. 
 
Figure 7. Structure of Dox-loaded, PEGylated, enzyme-sensitive, macrocyclic pillar[5]arene 
amphiphiles and their self-assembly into micelles. Adapted with permission from Ref. [101]. 
 
(b)  (a)  
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Folic acid (FA) surface-functionalized, biodegradable poly(ethylene oxide)-b-poly(L-glutamic 
acid) (FA-PEG-b-PLG) block copolymer vesicles loaded with cisplatin were also reported [102]. 
The drug was released intracellularly from the rigid block due to overexpressed Cathepsin B 
which cleaved the nanostructure because of the increased activity of this proteolytic enzyme in 
metabolizing PLG acid residues. The enzyme was also responsible for the higher activity in 
metabolizing polyglutamate (PGA) residues. The nanovesicles exhibited surface-positioned FA 
moieties for active targeting via selective cell binding and led to enhanced cytotoxicity towards 
HeLa cells. 
PGA was also used as a polymer scaffold to link both Ptxand an integrin-targeted ligand 
(E-[c(RGDfK)2]) on the side chains, to give PGA-Ptx-E-[c(RGDfK)2]). The resulting conjugate 
gave significant enhancement in anticancer activity compared to free Ptx [103]. As assessed by 
the in vitro drug release profile, Ptx was released in the presence of Cathepsin B but PGA-Ptx-E-
[c(RGDfK)2] was found to be stable in plasma. Interestingly, incorporation of a targeting ligand 
towards integrin expressing cells led to anti-angiogenic mechanism to overcome multi-drug 
resistance. 
Another targeted drug delivery system was reported and consisted in a heterobifunctional 
oligomeric PEG chains embedding octreotide as a ligand for the targeting of somatostatin 
receptors and either an anticancer drug (Dox) tethered via a dipeptidic substrate for Cathepsin B, 
or a fluorescent dye [104]. This oligomeric prodrug system was suitable for tumor cell imaging 
expressing both Cathepsin B and somatostatin receptors and led to selective cytotoxicity towards 
cancer cells.  
 
 
2.1.2 Inorganic systems 
Inorganic materials (e.g., silica, gold, iron oxide, quantum dots, etc.)is also an attractive family 
of materials that have been extensively investigated for anticancer drug delivery [105-111]. In 
this area, a Cathepsin B-induced tumor targeted drug delivery system loaded with Dox was 
developed by immobilizing cleavable rotaxanes onto mesoporous silica nanoparticles (MSNs) 
[112]. Nano-constructs comprising a rotaxane moiety and a GFLG sequence linked to the RGDS 
peptide were used as Cathepsin B-cleavable stoppers for the cyclodextrin valves by means of 
“click” chemistry (Figure 8). Thanks to the targeting ligand displayed at its surface, such system 
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demonstrated efficient receptor-mediated tumor cell uptake and selective enzymatic digestion of 
GFLG peptide.  
 
 
Figure 8. (A)Mesoporous silica nanoparticle (MSN) functionalization. (B) Cathepsin-sensitive 
Dox-loaded MSNs. (C) Cell integrin receptor-mediated targeting by RGDS (Arg-Gly-Asp-Ser). 
(D) Endocytosis. (E) Drug release mediated by Cathepsin B. (F) Tumor cell death. Adapted with 
permission from Ref. [112]. 
 
MSNs were also coated with Cathepsin B-sensitive peptide sequences (alkynyl-
GIVRAKEAEGIVRAK-OH) through triazole rings and led to efficient Dox release (Figure 9). 
The study also proved that this peptide sequence was selectively cleaved by Cathepsin B as 
assessed by in vitro experiments [113]. 
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Figure 9. Synthesis of gatekeeper-supported functionalization with 3-
(azidopropyl)triethoxysilane capped with peptide sequence and further delivery of Doxby action 
of Cathepsin B. Adapted with permission from Ref. [113]. 
 
This peptide sequence was also anchored onto silica supports to develop nanoparticles with 
prevented release the loaded [Ru(bipy)3]
2+
 dye unless specific proteases are present [114]. In 
another study, an enzyme-cleavable peptide precursor conjugated to Dox was further linked onto 
the surface of silica-coated magnetic nanoparticles by using “click” chemistry (Figure 10) [115]. 
The nanocarriers exhibited efficient Dox release and selective intracellular Dox delivery into 
tumors with high Cathepsin B expression together with imaging of cancer cells.  
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Figure10. Synthesis of Dox-peptide-coated, magnetic silica nanoparticles cleaved by Cathepsin 
B for Dox release inside cancer cells. Adapted with permission from Ref. [115]. 
 
A dual enzymatic responsive nanoconstruct for pancreatic cancer therapy was engineered and 
relied on surface functionalization of CdSe/ZnS quantum dots (QDs) by an amphiphilic PEG-
GGPLGVRGK-NH2 polymer sensitive to matrix metalloproteinases (MMP-9), and by Gem via a 
GELG Cathepsin B substrate sequence [116]. Some of the PEG chains were also functionalized 
by cyclo-RGD as a tumor-homing ligand. The nanocarrier exhibited long circulating features and 
increased drug accumulation at tumor sites, resulting in successful delivery of Gem in BxPD-3 
cells because of their inherently elevated concentrations of Cathepsin B (Figure 11).  
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Figure11. Synthesis of Gem-loaded, decorated QDs and their dual enzymatic behavior. Adapted 
with permission from Ref. [116]. 
 
2.1.3 Dendrimeric/comb-like systems 
Dendrimers, which are perfectly monodisperse and highly branched 3D macromolecules, have 
been the topic of great attention especially as drug carriers [117-119]. For example, peptide 
dendrimers surface-functionalized by methoxy polyethylene glycol (mPEG) and Dox through the 
GFLG sequence have been designed [120]. The resulting enzyme-responsive dendrimer-GFLG-
Dox nanocarrier gave greater accumulation and retention in ovarian tumor cells(SKOV-3), 
leading to improved anticancer effect and no obvious systemic toxicity. Similarly, mPEG-
PAMAM dendrimers of different chain lengths for the formation of Dox-loaded magnetite 
nanoparticles have also been reported [121]. In this system, Cathepsin B was used to selectively 
degrade the dendritic shell to trigger sustained Dox release near the tumor cells. The concept of 
enzymatic breakdown of the nanocarrier may represent a new approach for controlled drug 
delivery systems. Also, Cathepsin B-responsive and amphiphilic PEGylated dendritic polymer-
drug conjugates (PEGylated dendron-GFLG-Dox) were obtained by “click” chemistry and led to 
enhanced antitumor efficacy (Figure 12). 
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Figure 12. Synthesis of amphiphilic PEGylated dendron-GFLG-Dox conjugate followed by its 
self-assembly into NPs. Adapted with permission from Ref. [121]. 
 
Another study reported on the combination of undecapeptide KKLFKKILKKL-NH2 with the 
GFLG sequence for the delivery of chlorambucil (CLB) [122]. The free drug was inactive (IC50 
= 73.7 to >100 μM) conversely to its prodrug (IC50 = 3.6 – 16.2 μM) on various cancer cell lines 
including MCF-7, PC-3, CAPAN-1, 1BR3G and SKMEL-28. CLB-Gly-OH was indeed released 
when Cathepsin B was present as evidenced by Cathepsin B enzymatic assays. Also, these 
studies supported the fact that CLB would be released in the lysosomal compartment. A 
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comparative study was reported between dendrimers based on mPEG conjugated to Dox via a 
Cathepsin B-cleavable Gly-Phe-Leu-Gly sequence and GFLG-free dendrimers [123]. The GFLG 
sequence-bearing nanoconstructs were formulated into nanoparticles exhibiting Cathepsin B-
sensitive drug delivery properties. The enhanced anticancer activity compared to that of free Dox 
was validated in vivo in a CT26 tumor xenograft mouse model. 
Asorbitol scaffold functionalized by octa-guanidine moieties and conjugated to Dox via a 
GLPG sequence, another peptidic substrate of Cathepsin B, was produced (Figure 13) [124]. 
This conjugate was efficiently taken up by the cells via electrostatic interaction between 
guanidine moieties and negatively-charged phospholipids/sulphates exposed at the surface of the 
cells. Dox was then released into lysosomes via selective cleavage by Cathepsin B. Enhanced 
cytotoxicity compared to that of free Dox was obtained on HeLa cells that are known to express 
Cathepsin B. 
 
 
Figure13. Schematic representation and proposed action mechanism of a sorbitol scaffold 
functionalized by octa-guanidine moieties and conjugated to Dox. Adapted with permission from 
Ref. [124]. 
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2.1.4 Lipidic systems 
A great amount of work is also currently been carried out to design lipid-based drug delivery 
systems either as drug-loaded lipidic nanocarriers or lipidic prodrug nanocarriers [125, 126]. 
However, examples of Cathepsin-sensitive lipidic drug delivery systems are rather scarce. For 
instance, when a lipidated Cathepsin B inhibitor (NS-629) was anchored into a liposome bilayer 
(Figure 14),its selective targeting and internalization into tumors and stromal cells was shown ex 
vivo and in vivo, confirming that using Cathepsin B as an efficient leverage for cancer diagnosis 
and treatment [127]. 
 
Figure14. Schematic representation showing conjugation of the lipidated Cathepsin B inhibitor 
(NS-629) at the surface of a liposome to target extracellular (EC) CathepsinB. Adapted with 
permission from Ref. [127]. 
 
Combination therapy, that relies on the simultaneous administration of at least two different 
drugs, is increasingly used to treat various diseases, including cancer [128, 129]. Combination 
therapy from cathepsin-sensitive lipidic systems was illustrated by the conception of 
methotrexate-methoxypoly(ethylene glycol)-1,2-distearoyl-snglycero-3-phosphoethanolamine 
(Mtx-MePEG-DSPE) prodrug micelles loaded with mitomycin C-soybean phosphatidylcholine 
(SPC-MMC) prodrugs [130]. This micellar system exhibited synergistic anticancer activity in 
presence of Cathepsin B because of the amide linker in between the polymer and the drugs, as 
opposed to the action of individual drugs. 
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2.1.5 Protein-based/peptidic systems 
Drug delivery systems based on proteins or peptides represent an appealing class of materials 
especially because of their biocompatibility [131-135]. For instance, proteinticles, which are 
proteins that can self-assemble inside cells into nanoscale particles, can be employed in many 
different biomedical applications owing to their enhanced biocompatibility, conversely to 
synthetic nanomaterials [136]. Conferring cathepsin-sensitivity to such systems have also been 
reported, especially for small interfering RNA (siRNA) delivery where it showed great potential 
against various cancers. For instance, proteinticles based on human ferritin were genetically 
engineered to display at their surface different functional peptides in a simultaneous manner, 
such as cationic peptides for self-assembling siRNA, cancer cell-targeting or cell penetrating 
peptide [137]. They led to enhanced siRNA capture, cancer cell targeting together with enhanced 
penetration into the cytoplasm of tumor cells. They were eventually cleaved by Cathepsin B for 
intracellular release of siRNA inside tumor cells, leading to efficient gene silencing. One of the 
greatest advantages of proteinticles is that such functional peptides of different nature can be 
evenly placed on their surface, depending on the tumor cell type through a simple genetic 
modification, thus making it a very versatile system for targeted siRNA delivery. Another study 
revealed the development of a polyglutamate amine (APA) nanocarriers containing miRNA and 
siRNA polyplexes which showed great accumulation into pancreatic tumor cells [138]. It was 
also shown that the release of miRNA occurred from APA-containing polyplex in the presence 
of Cathepsin B. 
Given the poor water-solubility of many anticancer drugs, a considerable amount of research has 
been done to improve their hydrophilicity by conjugation to hydrophilic moieties via Cathepsin-
sensitive linkers. For instance, Ptx has been conjugated to a highly water-soluble nucleolin 
aptamer (NucA) for the targeting of ovarian cancer with reduced off-site toxicity [139]. The 
resulting bioconjugate proved to be biologically stable as assessed by fluorescence resonance 
energy transfer (FRET) (Figure 15) and also inactive in the blood circulation. NucA was 
conjugated to the hydroxyl group at position 2’ of the drug via a dipeptide bond sensitive to 
Cathepsin B, which then got cleaved once inside the cells by Cathepsin B, thus triggering the 
anticancer mechanism. 
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Figure 15. Schematic illustration of the in vivo tracking of the degraded Cathepsin B-labile 
dipeptide bond linker exploiting FRET with fluorescein amidate (FAM) and dual-labeled 
rhodamine B (Rh) NucA-Ptx bioconjugate. Adapted with permission from Ref. [139]. 
 
The GFLG sequence was also embedded into a star-shaped peptidic prodrug structures that can 
be cleaved by Cathepsin B. This feature has been used to develop drug delivery vehicles for 2-
methoxyestradiol (2ME) which is a natural metabolite of estradiol with antiproliferative and anti-
angiogenic activities (Figure 16) [140]. 
 
 
Figure16. Representation of the degradation of star-shaped peptidic prodrug structures that can 
be cleaved by Cathepsin B.Adapted with permission from Ref. [140]. 
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In the context of combination therapy, a dual-functionalized linker bearing Dox and Ptx, and 
comprising a maleimide moiety for its subsequent coupling to albumin through its cysteine-34 
position, was designed [141]. Each drug was linked by a self-immolative para-aminobenzyloxy 
carbonyl linker and a cleavable dipeptide (Phe-Lys) sensitive to Cathepsin B, leading to drug 
release at the tumor site (Figure 17).A similar approach combining a polymer prodrug and a 
polymer-enzyme bioconjugate was used to selectively and rapidly deliver a cytotoxic drug to the 
target site [142]. 
 
Figure17. Structure of Cathepsin B-sensitive, dual-functionalized linker bearing Dox and Ptx, 
and comprising a maleimide moiety for its coupling to albumin. Adapted with permission from 
Ref. [141]. 
 
Pep42, which is a cyclic 13-mer oligopeptide, specifically binds to glucose-regulated protein 78 
and translocates into the lysosomal compartment [143, 144]. In this context, Pep42 was 
advantageously used to efficiently deliver Ptx and Dox into cancer cells for enhanced 
cytotoxicity [145]. More specifically, Pep42-prodrug bioconjugates containing a Cathepsin B-
sensitive linker were synthesized and facilitated the uptake of both cytotoxic agents for their 
delivery into cancer cells. 
 Nanoconstructs with methotrexate (Mtx) linked to a tuftsin-like peptide carrier via a 
GFLG spacer and several copies of a chemotactic targeting agent were designed [146]. These 
conjugates led to greater cytotoxic effect than free Mtx and represented potential candidates for 
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the specific targeting of cancer cells. Similarly, Dox-based dipeptide conjugates were designed 
and tethered to monoclonal antibodies (mAbs) recognizing tumor associated antigens on renal 
cell carcinoma and anaplastic large cell lymphoma [147]. The dipeptides were substrates for 
Cathepsin B and got cleaved with comparable kinetics. Importantly, both prodrugs were 70-fold 
more potent than free Dox. 
In another study, cytotoxic drug-carrying filamentous bacteriophages were chemically 
modified to tunedifferent key parameters (e.g., pharmacokinetics, biodistribution, 
immunogenicity)and compared to bare phages [148]. Anti-ErbB2 and anti-ERGR antibodies 
were used as targeting entities, whereas Dox was tethered to phages through an amide linkage 
and also to genetically-engineered Cathepsin-B (Figure 18). In vitro studies explained the good 
penetration into tumors cells by their needle-like structure. This conjugate can be seen as a novel 
drug-delivery platform which might solve many issues related to the hydrophobicity of drugs at 
the target specific sites. 
 
 
Figure18. Genetically engineered Cathepsin B-modulated bacteriophage conjugated to Dox. 
Adapted with permission from Ref. [148]. 
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2.2 Bone-targeting drug delivery systems 
The most common skeleton disorders are arthritis, osteoporosis, osteomyelitis, osteosarcoma as 
well as metastatic bone cancer [37, 149]. Bone metastasis is one of the most devastating stages of 
cancer [150]. In addition, there are several limitations associated with the systemic 
administration of drugs for bone treatment and bone-related diseases such as poor drug uptake at 
the target site, potential systemic toxicity as well as suboptimal efficacy [149]. Interestingly, 
there are examples in the literature describing Cathepsin-sensitive polymer conjugates for bone 
targeting purposes [151-154]. Therefore, drug delivery systems targeted towards bones can be 
adapted to bone diseases where the drug can be selectively delivered with minimal side effects 
[155]. 
In a similar fashion to what has been reported for anticancer therapy, HPMA was 
conjugated to prostaglandin E1 (PGE1) via a spacer sensitive to Cathepsin K, which is an enzyme 
overexpressed in osteoclasts [156]. The Cathepsin K-sensitive spacer comprised Gly-Gly-Pro-
Nle as the tetrapeptide sequence and a self-eliminating 4-aminobenzyl alcoholmoiety. 
Copolymerization of the resulting PGE1-containing HPMA macromonomer with HPMA yielded 
the desired PHPMA-PGE1conjugates,that released unmodified PGE1 after incubation with 
Cathepsin K. PHPMA was also post-functionalized by a D-aspartic acid octapeptide targeting 
ligand. Therefore, this new drug delivery system might be a solution to treat osteoporosis and 
other bone-related pathologies.  
Targeting inflammatory joints in rheumatoid arthritis (RA) was achieved by AWO54, a 
new prodrug that binds to endogenous albumin and was composed of Mtx, a spacer based on 
lysine and an enzyme-sensitive peptide linker linked to a maleimide moiety for further linkage to 
albumin [157]. The prodrug was cleaved by two enzymes, Cathepsin B and plasmin, that exist in 
high concentrations in synovial effusion under RA condition, thus releasing Mtx lysine 
derivatives. The in situ coupling of endogenous albumin, AWO54 was found to be better in 
terms of dosage and efficacy than administration of the parent drug for treating collagen-induced 
arthritis. 
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2.3 Immune cell-targeting drug delivery systems     
Lysosomal peptidases are part of innate and adaptive immune responses [158-160]. Hence, 
modulation of such responses with Cathepsin-sensitive prodrugs can further enhance the 
immunological action and regulate cytotoxicity issues related to NK and T cells. For instance, 
influence of superparamagnetic iron oxide nanoparticles (SPIONs) from both a physiological and 
immunological point of view was investigated on cell function and their interaction with 
oxysterol laden cells [161]. Iron-loaded nanoparticles upregulated Cathepsin, membranous 
ferroportin (cellular efflux channel for iron) and ferritin degradation, which further altered 
cellular immune functions, resulting in secretion of pro- (TNF-α) and anti-inflammatory (IL-10) 
cytokines and ferritin. Importantly, this study highlighted a specific relationship between SPION 
metabolism and atheroma cellfunction that might conduct to innovative approaches to treat 
atherosclerotic plaques. 
Immunoconjugates were also prepared from cytotoxic agents using a valine-alanine-p-
aminobenzyl-amine linker which was well-adapted for the bioconjugation to monoclonal 
antibody and further specific cleavage by proteases [162]. The linker efficiently released amino-
geldanamycin and streptonigrin upon protease-mediated hydrolysis, emphasizing the activity and 
specificity of the conjugates in vitro and in vivo. In another study, different immunoconjugates 
comprising lysosomally cleavable peptides (i.e., Phe-Lys and Val-Cit), were synthesized [163]. 
The monoclonal antibody BR96 that is known to bind to Lewis
y
-related tumor-associated antigen 
expressed at the surface of cancer cells was linked to Dox via a p-aminobenzyloxycarbonyl 
(PABC) spacer. Interestingly, the conjugates bearing the Phe-Lys sequence exhibited a 30-fold 
greater drug release kinetics in the presence of Cathepsin B than its counterpart with the Val-Cit 
linker.  
 
2.4 Cathepsins as probes for imaging and theranostic 
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Different types of enzymes (e.g., caspases, secretases, furinases, phosphatases, etc.) have been 
exploited for cancer diagnosis. Furthermore, imaging probes utilizing these proteases have 
rapidly evolved [164-167]. It has been shown that the monitoring of protease activity was closely 
related to cancer progression especially in case of Cathepsin B [168]. Among the numerous 
studies on proteases for such a purpose, hollow mesoporous silica nanoparticles loaded with Dox 
and conferred with a dual-enzyme sensitivity were conceived for the in situ imaging of Cathepsin 
B and the release of Dox mediated by proteases (Figure 19) [169]. The peptide-based 
satellite/shell structures secured Dox inside the nanoparticles thus acting as three-dimensional 
gatekeepers and Dox release subsequently occurred upon incubation with Cathepsin B. 
 
Figure 19. Illustration of Dox-loaded, hollow mesoporous silica nanoparticles for in situ imaging 
of Cathepsin B and protease-mediated Dox release. (a) Nanoparticle synthesis. (b) Nanoparticle 
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disassembly mediated by enzyme cascade reactions with acid hyaluronidase (HAase) and 
Cathepsin B (Cat B). (c) Specific delivery, controlled Dox release and intracellular imaging: (i) 
specific uptake via receptor-mediated endocytosis; (ii) accumulation in endosomes; (iii) 
endosomal escape and intracellular imaging of Cat B; (iv) Dox release triggered by enzymes. 
Adapted with permission from Ref. [169]. 
It was also recently discovered that indocyanine green (ICG)–containing PGA nanoparticles can 
be digested byCathepsin B and induce a sentization of the endo-lysosomal membrane mediated 
by the NIR properties of the released ICG (Figure 20) [170]. The system was combined with a 
ribosome-inactivating protein (saporin) which showed synergistic cytotoxicity because of the 
photo-induced release of saporin from endosomes or lysosomes. 
 
 
Figure 20. (a) Sentization of endo-lysosomal membrane in the presence of dye released by 
enzymatic digestion of the nanoparticles. (b) Endo-lysosomal disruption by NIR laser leading to 
saporinrelease. Adapted with permission from Ref. [170]. 
 
An enzymatically dependent FRET process was also used to monitor the payload release from 
PHPMA prodrug nanocarriers [171]. PHPMA was functionalized with donor Cy5 and acceptor 
Cy7, thus inducing FRET. However, since only Cy7 was linked to the polymer via the GFLG 
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sequence, presence of Cathepsin B was accurately measured because of the change in the FRET 
signal during the Cathepsin B-mediated Cy7 release (Figure 21). The in vitro results showed that 
the high level of expression of Cathepsin B in cancer cells induced effective release of the dye 
while in vivo observations resulted in a faster release in the ovarian tumor as compared to normal 
tissues.  
 
 
Figure 21. Structure of dual-functionalized PHPMA nanocarriers with Cy5 and Cy7 dyes for 
further Cathepsin B-mediated release of Cy7. Adapted with permission from Ref. [171]. 
 
Similarly, PHPMA was functionalized with Cy5 (acceptor fluorophore) and Cy3 (donor 
fluorophore) or epirubicin (EPI) through a GFLG linker and evaluated by FRET during cell 
uptake and intracellular drug delivery experiments (Figure 22) [172]. Thanks to the Cathepsin B-
sensitive linker, the conjugates bearing EPI (2P-EPI) led to a fourfold terminal half-life 
compared to first generation (P-EPI) conjugate and complete tumor remission with ~100 days 
inhibition of tumorigenesis in mice. 
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Figure22. Schematic structure of PHPMA functionalized by Cy5 and EPI for further FRET-
monitoring of the EPI release mediated by Cathepsin B. Adapted with permission from Ref. 
[172]. 
 
The specific presence of cysteine Cathepsins has also been exploited to perform radiolabeled 
drug delivery for nanoscale conjugates with the aim of inducing enhanced diagnostic and 
radiotherapeutic efficacy. For instance, PHPMA was radiolabeled with Lutetium-117 (
117
Lu) via 
a peptide sequence made of two consecutive metabolically active linkers (MALs) sensitive to 
Cathepsin B and S, that are overexpressed in the liver and the spleen [173]. The MALs were 
shown to be metabolized by enzymes into single metabolites. The 
117
Lu-peptide-PHPMA 
conjugate showed a substantial retention decrease in the long run in the liver and the spleen, 
compared to non-cleavable counterparts on human pancreatic adenocarcinoma xenograft mouse 
model. In another study, the Garrison’s group developed the synthesis of cathepsin S-susceptible 
177
Lu-labeled or FRET-capable multiblock PHPMA copolymers, which resulted into fast in vitro 
cleavage of both copolymers. Quicker clearance and lower non-target retention without reducing 
tumor targeting was also shown on pancreatic ductal adenocarcinoma mouse model [174]. This 
study therefore took benefit of the presence of Cathepsin S in MPS tissues to lower non-target 
accumulation. 
 
A targeted, theranostic prodrug relying on Cathepsin-B-sensitive Gem release and 
activation of a caspase-3 specific probe was designed (Figure 23) [175]. The targeting relied on 
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the RGD peptide for accumulation into pancreatic cancer cells with overexpressed αvβ3 integrin. 
The GFLG peptide was then hydrolyzed by Cathepsin B leading to Gem release as well as the 
apoptotic probe. This system showed promising properties as a platform for both pancreatic 
cancer cell targeting and real-time, non-invasive imaging. 
 
 
Figure23. Schematic structure of consecutive enzymatic reaction using a gemcitabine-based 
prodrug along with apoptotic probe for the killing and monitoring of pancreatic cancer cells. 
Adapted with permission from Ref. [175]. 
 
In tumor imaging, many proteases can be used for the activation of fluorescent probes including 
near-infrared emitting dyes. Therefore, in vivo molecular profiling of protease activity can be 
performed with such probes in endoscopy or tomographic optical imaging [176]. For instance, it 
has been reported the design of quenched activity-based probe (qABP) mediated by Cathepsin S 
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[177]. It showed high tumor-specific fluorescence in a syngeneic breast cancer model. Other 
activity-based probes targeting Cathepsin X have been designed [178]. Cathepsin X is involved 
in a many different biological mechanisms, such as aging, cancer, neurodegenerative disorders, 
inflammation, etc. [179-181]. These probes were successfully used for the selective labeling and 
imaging of Cathepsin X in vitro and in vivo, thus making them a valuable tool for examining 
protease activity and functions.  
Malarial parasites are known to generate significant concentrations of mobile ferrous iron [182]. 
In this context, parasite-specific, Fe
II
-sensitive delivery of a potent dipeptidyl aminopeptidase 
inhibitor through Cathepsin C was demonstrated by using activity-based probes [183]. 
Production of Fe
II
 was triggered in the presence of 1,2,4-trioxolone moiety leading to instant 
drug release prior to the fragmentation of the aforesaid moiety. Further in vivo evaluation was 
performed using Plasmodium berghei model of murine malaria which showed selective drug 
targeting in parasitic infections.  
Cathepsin D-conjugated peptides were self-assembled into nanoparticles with the help of 
gelatin to bypass early nonspecific dissolution as well as off-target Dox release and is useful for 
optical imaging in animal models [184]. Cathepsin D is an enzyme for breast cancer cell 
secretion, which got triggered by degrading the nanoparticles coated with peptide strands 
through hydrolytic cleavage, thus releasing Dox. The nanoparticles were evaluated under 
ultrasound imaging both in vitro and in vivo, and were found to be localized in the bladder and 
the tumors of mice as a result of the fluorescent profile of Dox. Synthesis of Cathepsin B-
sensitive, near-infrared fluorescent probe was also carried out (Figure 24) [185]. The probe was 
found to be water-soluble but still self-assembled into nanoparticles having potential for tumor-
targeted imaging. A fluorescent molecule, DCPO (dicyanomethylene-4H-pyran), was released by 
Cathepsin B, leading to in vitro imaging Cathepsins of various tumor cells during incubation 
with different cell lines. 
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Figure24. Chemical structure of NIR fluorescent probe sensitive to CathepsinB [185]. 
 
Similarly, a Cathepsin B-sensitive nanoparticulate probe comprising a Cathepsin B substrate 
peptidic probe linked to chitosan nanoparticles was reported [186]. According to the study, this 
probe was successfully delivered into tumor cells after nanoparticle accumulation and exhibited 
fluorescent signals inside the cytosol in presence of Cathepsin B. It thus showed increased 
potential for the optical detection of biological activities especially related to tumor growth or 
metastasis (Figure 25).  
 
 
Figure25. Cathepsin B-sensitive nanoparticulate probes and tumor diagnosisin vivo. Adapted 
with permission from Ref. [186]. 
 
Recently, another strategy was used for Cathepsin imaging in breast cancer. It relied on a 
selective fluorogenic substrate and activity-based probe for the specific imaging of Cathepsin L 
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[63]. This approach enabled to differentiate Cathepsin L activity from that of other Cathepsins 
such as Cathepsin B. 
 
2.5 Miscellaneous 
As shown in the previous sections, Cathepsins have been exploited in targeted drug delivery 
systems and imaging. However, Cathepsin inhibitors can also be exploited in regard to their role 
in numerous diseased conditions, mainly cardiovascular diseases such as myocardial infarction, 
atherosclerosis, cardiac hypertrophy, cardiomyopathy and hypertension based on animal models 
[187]. Cathepsin inhibitors are also used against immune responses, osteoporosis, arthritis, 
inflammation and neurodegenrative disorders [36, 188-190]. A selection of representative 
examples is discussed below.  
Interestingly, peptide-based pseudosubstrates for Cathepsin G and elastase were 
developed. These substrates can decrease the activated interleukin-36 (IL-36) family cytokines 
especially in case of inflammatory diseases(e.g., psoriasis, arthritis)because such cytokines are 
proteolytically processed in the presence of Cathepsin G and other proteases [191]. In another 
study, it was proven that amodiaquine, an antimalarial drug, inhibited host Cathepsin B to protect 
host cells against infection with multiple toxins or viruses [192]. Cathepsin K has also been 
involved in diabetes-associated cardiac abnormalities. Wild-type as well as Cathepsin K 
knockout mice-induced diabetes exhibited severe cardiac dysfunctions in the form of dampened 
calcium handling intracellularly, cardiac morphology alterations and also increase in 
cardiomycyte apoptosis [193, 194]. Hence, Cathepsin K may be a suitable target in the afore-
mentioned conditions. One study also investigated cysteine Cathepsin inhibitors such as GB111-
NH2 (that blocks the activity of Cathepsin B, L and S) as trigger in macrophage cell death 
especially in case of tumor-associated macrophages (TAMs) [195]. 
 
3. Clinical data on cathepsins 
As seen throughout this review article, PHPMA has been extensively used for the design of 
Cathepsin-sensitive nanocarriers. This is explained by the favorable properties of PHPMA 
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regarding biomedical applications. PHPMA is indeed hydrophilic, non-immunogenic, chemically 
inert, non-toxic (even at the dose of 30 g/kg rat), biocompatible and exhibits relatively long 
circulation time which is dependent on its molar mass [196]. Among the different conjugates 
based on PHPMA that have been synthesized and evaluated so far, some of them entered clinical 
trials (Table 2). In particular,PK1 (Prague-Keele-1) has shown very promising results in 
oncology [197] and reached phase II trials in 2002 but clinical studies for both PK1 and PK2 
were discontinued in 2008 because of lack of efficacy [198]. Other polymeric systems also 
entered clinical trials (Table 2). For instance, XYOTAX (based on polyglutamate) has shown 
encouraging results in phase III trials in women with non-small-cell lung cancer [199-205]. 
Among the different PHPMA clinical candidates, PNU166945 is based on Ptx for the treatment 
of advanced breast cancer and PNU166148 is based on camptothecin for the treatment of 
metastatic solid tumors but both were stopped in Phase I trials because of severe neurotoxicity 
and lack of anticancer action, respectively [206, 207].Also, AP5280 prodrug has been introduced 
for PHPMA-carboplatinate and entered clinical phase II trial whereas PHPMA-oxiplatinate 
(ProLindac, also named AP5346) was in clinical phase II trial against ovarian cancer [208-210]. 
PHPMA polymer conjugated to Dox using GFLG linker has also been attempted with protein-
bound Ptx (abraxane), carbohydrate residues such as galactosamine, lactose and also amino acids 
like phenylalaninelysine (Phe-Lys), and are currently in preclinical studies [211-214].On the 
contrary, high molar mass PHPMA was investigated to enhance the anticancer efficacy which 
also reached preclinical settings [215]. A second series of blockbuster polymers that entered 
clinical trials are PEG-based conjugates, namely, EZ-246 conjugated to camptothecin but its 
phase II trials has been stopped due to lack of efficacy. However, NK911 in the form of 
PEGylated micelles with aspartic acid and Dox had showed promising efficacy against various 
solid malignancies likely thanks to the EPR effect and is currently in phase II [216-219]. 
Carboxymethyldextrans another synthetic polymer forming prodrugs with exatecan and 
camptothecin [220], and which entered Phase I clinical trials, showed prominent results 
especially against colon cancer [221, 222]. Polyglutamate has been conjugated using Ptx by Cell 
Therapeutics Inc. company and is currently in Phase II trials [199, 200]. Other Cathepsin-
sensitive drug delivery systems are under preclinical investigations, including polymeric 
dendritic systems containing Dox (KTB Tumorforschungs GmbH company) [223, 224]. 
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Table 2.List of Cathepsin B-Cleavable Prodrugs Evaluated inClinical Trials. 
Entry Name Composition Spacer Linker 
Clinical 
Trial 
status 
Company Refs 
1 
PK1; 
FCE28068 
PHPMA 
copolymer-
Doxorubicine 
Gly-Phe-Leu-
Gly 
Amide 
Phase II 
(discontinu
ed) 
Pfizer 
Inc., 
Cancer 
Research 
Campaign
, UK 
[196, 
225] 
2 
PK2; 
FCE28069 
PHPMA-Dox-
Galatosamine 
Gly-Phe-Leu-
Gly 
Amide 
Phase 
I/II(disconti
nued) 
Pfizer 
Inc., 
Cancer 
Research 
Campaign
, UK 
[226, 
227] 
3 
PNU166945/H
PMA-Ptx 
PHPMA 
copolymer- 
Paclitaxel 
Gly-Phe-Leu-
Gly 
Ester 
Phase 
I(discontinu
ed) 
Pharmacia [206] 
4 
PNU166148/H
PMA-
CPT/MAG-
CPT 
PHPMA 
copolymer-
Camptothecin 
Glycine 
residue/ 
Glycylaminoh
exanoyl 
spacer 
Ester 
Phase 
I(discontinu
ed) 
Pharmacia [207] 
5 
CT-2103/PGA-
Ptx-
XYOTAXTM/
OPAXIO® 
Polyglutamate-
Paclitaxel 
 
L-glutamic 
acid 
Ester Phase II/III 
Cell 
Therapeut
ics Inc. 
[199-
205] 
6 
CT-2106/PGA-
CPT 
Polyglutamate-
Camptothecin 
L-glutamic 
acid 
Ester 
Phase II 
discontinue
d 
Cell 
Therapeut
ics Inc. 
[228-
230] 
7 AP5280 
PHPMA 
copolymer- 
Carboplatinate 
Gly-Phe-Leu-
Gly 
Aminoma
lonate 
Phase I 
Access 
Pharmace
uticals 
Inc. 
[208, 
209] 
8 
AP5346/ 
ProlindacTM 
PHPMA 
copolymer-
DACH 
Oxiplatinate 
GGG-
carboxylate-Pt 
coordination 
Aminoma
lonate 
Phase II 
Access 
Pharmace
uticals 
Inc. 
[210] 
9 
EZ-246/PEG-
CPT/Pegamote
can/ProthecanT
M 
PEG-
Camptothecin 
Glycine Ester 
Phase II 
discontinue
d 
Enzon 
Pharmace
uticals, 
Inc. 
[216, 
217] 
10 NK911 
PEG-aspartic 
acid-
Doxorubicinmi
celle 
Aspartic acid Amide Phase II 
National 
Cancer 
Institute 
Japan 
[97, 
218, 
219] 
11 P-Dox 
PHPMA 
copolymer-
Gly-Phe-Leu-
Gly 
Amide Preclinical - 
[211, 
212] 
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Dox 
12 
P-(GFLG)-
Dox-Ab 
PHPMA 
copolymer-
Dox-abraxane 
Gly-Phe-Leu-
Gly 
Amide Preclinical - [213] 
13 
P-(GFLG-
Dox)-Ga IN 
PHPMA 
copolymer-
Dox-N-
acylated 
galactosamine 
Gly-Phe-Leu-
Gly 
Amide Preclinical - [214] 
14 
P-(GFLG-
Dox)-Lac 
PHPMA 
copolymer-
Dox-Lactose 
Gly-Phe-Leu-
Gly 
Amide Preclinical  [214] 
15 HMW1D 
PHPMA 
copolymer-
Dox (high 
molecular 
weight) 
Gly-Phe-Leu-
Gly 
Amide Preclinical - [215] 
16 TET1D 
PHPMA 
copolymer-
Dox (non-
targeted) 
Gly-Phe-Leu-
Gly 
Amide Preclinical - [215] 
17 
DOXO-EMCH 
(INNO-206) 
EMC-Arg-Arg-
Ala-Leu-Ala-
Leu-Dox 
Ala-Leu-Ala-
Leu 
Maleimid
e 
Preclinical 
CytRx 
Corporati
on 
[231] 
18 
EMC-Phe-Lys-
PABC-Dox 
PHPMA 
copolymer-
Phe-Lys-
PABC-Dox 
Phe-Lys Amide Preclinical 
KTB 
Tumorfor
schungs 
GmbH 
[223] 
19 
PG-Phe-Lys-
Dox 
Hyperbranched 
polyglycerol-
Phe-Lys-Dox 
Phe-Lys Amide Preclinical 
KTB 
Tumorfor
schungs 
GmbH 
[224] 
20 DE-310 
Carboxymethyl
dextran-
exatecan 
Gly-Phe-Leu-
Gly 
Amide Phase I 
Daiichi 
Pharmace
utical Co. 
Ltd. 
[221] 
21 
Delimotecan 
(MEN 4901/T-
0128) 
Carboxymethyl
dextran-
camptothecin 
Triglycine Ester Phase I 
Mitsubish
i 
Tanabe/M
enarini 
[222] 
 
 
 
37 
 
4. Conclusion 
As shown in this Review Article, Cathepsins could be very efficient tools, leverages or even 
actuators for the design of advanced drug delivery systems. It has been shown that these systems 
were sensitive to the presence of a broad spectrum of different Cathepsins, leading to enhanced 
therapeutic benefit and imaging capabilities. Among the numerous Cathepsin-sensitive 
conjugates reported so far, some of them have shown promising results and even reached 
advanced clinical trials. However, a great deal of work remains especially regarding the lack of 
site specificity and the still limited understanding of the biological roles of some proteases. 
These limitations must be resolved to develop optimized conjugates and offer more prominent 
clinical candidates. 
Also, it has been demonstrated that cysteine Cathepsin proteases can act as regulators for 
cancer progression as well as therapeutic response [232]. It means that they can either promote 
tumor growth or suppress tumor depending upon the environment. However, more clinical 
investigations must be performed to have a complete and accurate picture of the situation in vivo. 
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